Patient Selection Criteria: Identifying Appropriate Candidates for Tarlatamab

EP: 1.ES-SCLC vs LS-SCLC: Critical Differences in Disease Burden and Patient Prognosis

EP: 2.Current Treatment Paradigm: Evolution of First-Line Therapy for ES-SCLC

EP: 3.Addressing Critical Unmet Needs in ES-SCLC Patient Management

EP: 4.Emerging Clinical Trials: Novel Approaches in Second-Line ES-SCLC

EP: 5.Institutional Implementation: Setting Up Tarlatamab Administration

EP: 6.Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation

Now Viewing

EP: 7.Patient Selection Criteria: Identifying Appropriate Candidates for Tarlatamab

EP: 8.Tarlatamab Administration and Postinfusion Monitoring

EP: 9.Essential Patient and Caregiver Education for Tarlatamab Treatment Success

EP: 10.Neurological Toxicity Recognition: ICANS Assessment and Management

EP: 11.CRS Recognition and Intervention: Timing and Clinical Features

EP: 12.Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue

EP: 13.Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies

EP: 14.Standardized Toxicity Grading: Institutional Protocols for CRS and ICANS

EP: 15.Future Research Priorities: Optimizing Tarlatamab Administration and Toxicity Management

EP: 16.Seamless Transitions: Managing the Inpatient to Outpatient Care Continuum

EP: 17.Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical Benefit

Summary for Physicians:

Clinical Factors for Tarlatamab Eligibility:

• Good candidates:
• Relapsed/refractory small cell lung cancer after prior treatments
• Adequate organ function (eg, liver, kidney)
• ECOG performance status: Typically 0-1 (able to carry out normal activities or minimal assistance needed)
• Impact of treatment history:
• Chimeric antigen receptor T-cell therapy or bispecifics: May affect eligibility due to prior immune system manipulation; consider potential cross-reactivity or previous toxicities.
• Chemotherapy: Previous treatment may influence eligibility, especially if there are complications (eg, neuropathy or compromised organ function).

Prior therapies may also alter immune system response, impacting effectiveness.